Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
Key facts
- Who runs it
- Poitiers University Hospital
- Where
- France37 sites in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 224 people, planned
- Started
- 19 Dec 2018
- Expected to end
- Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- inhaled Ambisome®
- inhaled placebo
- Itraconazole
- Record updated
- 20 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- All adult patients affected with Chronic Pulmonary Aspergillosis (CPA) "de novo" or in relapse (without any history of resistance to itraconazole) combining the following criteria are eligible:
- Patient with an Aspergillus bronchopulmonary infection, be it cavitary, fibrotic, necrotizing (SIA/Semi Invasive Aspergillosis) or nodular and documented by compatible thoracic CT-scan images
- Associated with one of the following criteria:; positive detection of anti-Aspergillus IgG and/or precipitating anti-aspergillus antibodies, according to the positivity threshold of the laboratory performing the technique,; positive direct examination of Aspergillus or positive culture, from bronchopulmonary samples (expectoration or endoscopic aspiration),; revealing aspergillar hyphae/filaments on histological samples
- Men or women age ≥ 18 years
- For the women of childbearing age: women having a negative serum pregnancy test, having a contraception highly effective and accepting to pursue it during at least the first 12 months of the study
- Patient legally free and not subject to any custody, guardianship, tutelage or subordination measures
- Participants must be affiliated to France's Health Care Regime (" Sécurité Sociale ")
- Free and informed consent signed by each participating patient
Who cannot take part
- - Patient presenting a contraindication to itraconazole (including all contraindicated co-administrated medications as listed in the itraconazole SmPc, including notably medications with potential to prolong theQT interval)
- - Patient presenting a contraindication to voriconazole and posaconazole (including all contraindicated coadministrated medications as listed in the SmPc)
- - Patient having presented complications related to a previous treatment by nebulised LAmB
- - Patient received an oral (excepted oral Amphotericin B), parenteral or intra-cavity antifungal treatment within the last 2 months
- - Concomitant use of one or several of treatments contra-indicated with the experimental or non-experimental treatment
- - Chronic Pulmonary Aspergillosis with indication for surgical intervention within 6 months from the start
- - Threatening hemoptysis, with impossibility to defer surgical procedures (but patients contraindicated to surgery may be included after resolution of the hemoptysis)
- - History of hypersensitivity reaction to liposomal amphotericin B or to itraconazole or to any other constituent
- - Invasive pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
- - Tuberculosis or progressive non-tuberculous mycobacteria
- - Respiratory infection aggravating the underlying CPA (patient may be included after eradication of infection)
- - Severe renal failure (clearance <30 ml / min)
- - Hepatic failure with transaminase and alkaline phosphatase values > 5 times normal
- - Significant abnormality of the blood cell and platelet counts (at the discretion of the investigator)
- - Ventricular dysfunction such as congestive cardiac failure or history of congestive cardiac failure or patients with risk(s) factors of cardiac arrhythmia or symptomatic arrhythmia with a prolongation of the corrected QT interval > 450 msec in men and 470 msec in women or treated by medication known to prolong QT interval, or prolongation of the corrected QT interval > 450 msec in men and 470 msec in women
- - Women at age to procreate and not using highly effective contraception, pregnant or breastfeeding women
- - Patient affected with single aspergilloma
- - Intolerance to beta2-agonists
- - Notion of relapse with isolation of an Aspergillus resistant to itraconazole
- - Patients with Cystic Fibrosis
- - Immunocompromised patients
- - Patient refusing to participate
- - Protected majors in the meaning of the law, non affiliated persons or with no social security scheme, persons deprived of liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergencies
- - Patient in exclusion period following participation in another interventional study evaluating antifungals or medicines
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or mildly - immunocompromised patients affected by Chronic Pulmonary Aspergillosis (single aspergilloma excluded).
Read full original descriptionShow less
• Control arm: Itraconazole 200 mg x 2/day associated with inactive nebulised treatment twice a week during 24 weeks.
• Experimental arm: Itraconazole 200 mg x 2/day associated with nebulised LAmB, at 25 mg twice a week during 24 weeks.
Follow up duration for the patients will be 24 months (12 months minimum) after discontinuation of the treatment being studied.
The 2 groups in the trial
- Itraconazole & inhaled placeboPlacebo, for comparison
Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
Treatment: inhaled placebo and Itraconazole
- Itraconazole & inhaled Ambisome®Treatment being tested
Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
Treatment: inhaled Ambisome® and Itraconazole
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome® Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients with Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single Blind Study, (single Aspergilloma Excluded)
- Record updated
- 20 February 2025